急性重症自身免疫性肝炎治疗研究进展

肝脏 ›› 2022, Vol. 27 ›› Issue (3): 370-372.

急性重症自身免疫性肝炎治疗研究进展

蒋妮, 李俊峰, 李敏, 毛小荣

730000 甘肃兰州大学第一医院感染科

收稿日期:2021-10-18 出版日期:2022-03-31 发布日期:2022-05-31
通讯作者: 毛小荣,Email:mxr2013@126.com
基金资助:
甘肃省自然科学基金项目(20-JR5RA364);兰州大学第一医院院内基金(ldyyyn2017-10);甘肃省卫生行业科研计划项目(GSWSKY2017-45)

Received:2021-10-18 Online:2022-03-31 Published:2022-05-31

摘要/Abstract

摘要： 急性重症自身免疫性肝炎(AS-AIH)是一种罕见的疾病,因其不具有典型临床及实验室特征预,故诊治困难,预后差,目前临床尚无标准治疗规范。文章从AS-AIH患者治疗方面着手,从不同人群对治疗方法(皮质醇类固醇激素、其他免疫抑制剂、肝移植等)的选择,治疗效果预测指标、评价指标等方面最新研究成果进行综述。

蒋妮, 李俊峰, 李敏, 毛小荣. 急性重症自身免疫性肝炎治疗研究进展[J]. 肝脏, 2022, 27(3): 370-372.

[1] Purnak T, Efe C, Kav T, et al. Treatment response and outcome with two different prednisolone regimens in autoimmune hepatitis. Dig Dis Sci, 2017, 62: 2900-2907.
[2] Hartl J, Ehlken H, Sebode M, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. J Hepatol, 2018, 68: 754-763.
[3] Pape S, Gevers TJG, Belias M, et al. Predniso(lo)ne dosage and chance of remission in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol, 2019, 17:2068-2075.
[4] Yeoman AD, Westbrook RH, Zen Y, et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol, 2014, 61:876-882.
[5] Ichai P, Duclos-Vallée JC, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl, 2007, 13: 996-1003.
[6] Zachou K, Arvaniti P, Azariadis K, et al. Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in ptients with original acute severe autoimmune hepatitis. Hepatol Res, 2019, 49: 96-104.
[7] Fujiwara K, Yasui S, Yonemitsu Y, et al. Analysis of infectious complications and timing for emergency liver transplantation in autoimmune acute liver failure. J Hepatobiliary Pancreat Sci, 2016, 23: 212-219.
[8] Verma S, Maheshwari A, Thuluvath P. Liver failure as initial presentation of autoimmune hepatitis: clinical characteristics, predictors of response to steroid therapy and outcomes. Hepatology, 2009, 49:1396-1397.
[9] De Martin E, Coilly A, Houssel-Debry P, et al. Treatment and prognosis of acute severe autoimmune hepatitis. J Hepatol, 2017, S0168-8278.
[10] Jimenez-Rivera C, Ling SC, Ahmed N, et al. Incidence and characteristics of autoimmune hepatitis. Pediatrics, 2015, 136: 1237-1248.
[11] Llovet LP, Horta D, Eliz MG, et al. Presentation and outcomes of pregnancy in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol, 2019, 17: 2819-2821.
[12] Bajaj js, Garcia TG, Biggins SW, et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut, 2021, 70: 531-536.
[13] Buechter M, Manka P, Heinemann FM, et al. Potential triggering factors of acute liver failure as a frst manifestation of autoimmune hepatitis-a single center experience of 52 adult patients. World J Gastroenterol, 2018, 24: 1410-1418.
[14] Mendizabal M, Marciano S, Videla MG, et al. Fulminant presentation of autoimmune hepatitis: clinical features and early predictors of corticosteroid treatment failure. Eur J Gastroenterol Hepatol, 2015,27:64-648.
[15] Yeoman AD, Westbrook RH, Zen Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology, 2011, 53: 926-934.
[16] De Martin E, Coilly A, Houssel-Debry P, et al. Treatment and prognosis of acute severe autoimmune hepatitis. J Hepatol, 2017, S4.
[17] Moenne-Loccoz R, Severac F, Baumert TF, et al. Usefulness of corticosteroids as first-line therapy in patients with acute severe autoimmune hepatitis. J Hepatol, 2016, 65: 444-446.
[18] Rahim MN, Liberal R, Miquel R, et al. Acute severe autoimmune hepatitis: corticosteroids or liver transplantation? Liver Transplantation, 2019, 25: 946-959.
[19] Montano AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology, 2007, 46: 1138-1145.
[20] Martin ED, Coilly A, Chazouillères O, et al. Early liver transplantation for corticosteroid non-responders in acute severe autoimmune hepatitis: the SURFASA score.J Hepatol, 2021,76: 1325-1334.
[21] Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology, 1988, 95: 448-453.
[22] De Martin E, Coilly A, Ichai P, et al. The role of corticosteroids in acute-severe autoimmune hepatitis is still highly debatable. J Hepatol, 2015, 63:1041-1042.
[23] Yasui S, Fujiwara K, Haga Y, et al. Infectious complications, steroid use and timing for emergency liver transplantation in acute liver failure: analysis in a Japanese center. J Hepatobiliary Pancreat Sci, 2016, 23: 756-762.
[24] Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil assecond line therapy in autoimmune hepatitis? Am J Gastroenterol, 2008, 103: 3063-3070.
[25] Yeoman AD, Westbrook RH, Zen Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology, 2011, 53: 926-934.
[26] Hagstrom H, Ludvigsson J.Editorial: severe outcomes are rare in pregnancy with autoimmune hepatitis. Aliment Pharmacol Ther, 2018, 48: 1017-1018.
[27] 张勤建, 严建英. 妊娠合并自身免疫性肝炎. 实用妇产科杂志, 2021, 37: 575-578.
[28] Vollmer O, Felten R, Mertz P, et al. Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: an analysis of 389 cases in VigiBase. Autoimm Rev, 2020, 19: 102460.
[29] Halliday N, Dyson J K, Thorburn D, et al. Experimental therapies in autoimmune hepatitis. Aliment Pharmaco Therap, 2020, 52: 1134-1149.
[30] Nakao M, Nakayama N, Uchida Y, et al. Nationwide survey for acute liver failure and late-onset hepatic failure in Japan. J Gastroenterol, 2018, 53: 752-769.
[31] Ikegami T, Taketomi A, Soejima Y, et al. Living donor liver transplantation for acute liver failure: a 10-year experience in a single center. J Am Coll Surg, 2008, 206: 412-418.
[32] Montano-Loza AJ, Bhanji RA, Wasilenko S, et al. Systematic review:recurrent autoimmune liver diseases after liver transplantation. Aliment Pharmacol Ther, 2017, 45: 485-500.
[33] Nú?ez-Martínez O, De La Cruz G, Salcedo M, et al. Liver transplantation for autoimmune hepatitis: fulminant vs. chronic hepatitis presentation. Transplant Proc, 2003, 35:1857-1858.
[34] Ajanayagam J,Lewindon PJ. Infliximab as rescue therapy in paediatric autoimmune hepatitis. J Hepatol, 2013, 59: 908-909.
[35] Jossen J, Annunziato R, Kim HS, et al. Liver transplantation for children with primary sclerosing cholangitis and autoimmune hepatitis: UNOS database analysis. J Pediatr Gastroenterol Nutr, 2017, 64: e83- e87.
[36] Montano-Loza AJ, Bhanji RA, Wasilenko S, et al. Systematic review: recurrent autoimmune liver diseases after liver transplantation. Aliment Pharmacol Ther, 2017, 45: 485-500.
[37] Kerkar N, Yanni G. “De novo” and “recurrent” autoimmune hepatitis after liver transplantation: a comprehensive review. J Autoimmun, 2016, 66: 17-24.

急性重症自身免疫性肝炎治疗研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价